A personalized medicine approach is likely to be necessary to use ABT-199 in ovarian cancer and measurement of Bcl-2 expression in patients’ tumours seems advisable, particularly in light of the antagonism we have observed in some cell lines. Here, BCL2 is linked to ovarian carcinoma.